Background-In aortic valve stenosis (AS), the occurrence of heart failure symptoms does not always correlate with severity of valve stenosis and left ventricular (LV) function. Therefore, we tested the hypothesis that symptomatic patients with AS have impaired diastolic, longitudinal systolic function, and left atrial dilatation compared with asymptomatic patients. Methods and Results-In a retrospective descriptive study, we compared clinical characteristics and echocardiographic parameters in 99 symptomatic and 139 asymptomatic patients with severe AS and LV ejection fraction ≥50%. Independent predictors of symptomatic state were identified using logistic regression analysis. Symptomatic patients were younger (72±10 versus 76±12 years of age; P=0.002), presented less often with atrial fibrillation (13% versus 24%; P=0.05) and chronic obstructive pulmonary disease (2% versus 19%; P<0.001), and had a lower prevalence of hypertension (73% versus 40%; P<0.001). Despite similar AS severity, symptomatic patients had higher LV mass index (120±39 versus 95±25 g/m 2 ; P<0.0001), increased relative wall thickness (0.61±0.15 versus 0.50±0.11; P<0.0001), shorter mitral deceleration time (199±58 versus 268±62 ms; P<0.0001), and increased left atrial volume index (49±18 versus 42±15 mL/m 2 ; P=0.02). When adjusting for age, history of hypertension, atrial fibrillation, and chronic obstructive pulmonary disease in a multivariable logistic regression analysis, LV mass index, relative wall thickness, left atrial volume index, and deceleration time were still associated with the presence of symptoms. Conclusions-The present study demonstrates that symptomatic status in severe AS is associated with impaired diastolic function, LV hypertrophy, concentric remodeling, and left atrial dilatation when corrected for indices of AS severity. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00294775.
T he occurrence and severity of cardiac symptoms may correlate poorly with the severity of aortic valve stenosis (AS; aortic valve area [AVA] and transvalvular pressure gradients), and symptoms often occur despite preserved left ventricular (LV) ejection fraction (EF). 1 
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LV pressure overload may induce LV hypertrophy and myocardial fibrosis leading to increased chamber stiffness, delayed active LV relaxation, and compromised coronary flow reserve, all of which may affect diastolic and systolic function. It is thus possible that the development of symptoms in AS reflects alterations in LV morphology and function, leading to increased filling pressures and left atrial (LA) dilatation, hemodynamic, and morphological changes that may occur without any change in LVEF. Although LV hypertrophy is an independent predictor for the development of exertional dyspnea, 2 development of angina despite normal coronary vessels, 3 and is associated with the occurrence of increased LV filling pressure, 4 LV hypertrophy is also often present in asymptomatic patients with AS, underlining the need for further research to understand the mechanism leading asymptomatic patients with AS to become symptomatic. It is possible that diastolic dysfunction leading to LA pressure overload rather than LV hypertrophy itself is related to development of heart failure symptoms.
We thus tested the hypothesis that compared with asymptomatic patients, symptomatic patients with AS have impaired diastolic and longitudinal systolic function and LA dilatation.
Methods
In this study, we compared 2 different populations, all characterized by severe AS (AVA <1 cm 2 ), LVEF >50%, and no concomitant moderate or severe valve regurgitation. Only AVA was required for this study, ensuring that patients with low gradient severe AS were included. Symptomatic patients were included consecutively from February 2006 to May 2008; this population has previously been described in detail but consisted of patients referred for aortic valve replacement (AVR). 5 The asymptomatic cohort included consecutive patients seen by senior cardiologists at the outpatient clinic at the Vejle Hospital Department of Cardiology between January 2010 and December 2010, and, as a consequence of the clinical history and physical examination, were considered asymptomatic by the evaluating cardiologist and the referring physician.
In June 2012, data were collected retrospectively, and after thorough review of medical records, patients with LVEF <50%, AVA >1 cm 2 , or possible symptoms including dyspnea, edema, fatigue, angina, and syncope were excluded. In both populations, we also excluded patients with previous aortic valve surgery and concomitant moderate/severe aortic/ mitral regurgitation. The study was registered with the National Board of Health and the Danish Data Protection Agency and was approved by the local Scientific Ethical Committee; all patients gave written informed consent (ClinicalTrials.gov identifier: NCT00294775).
Because estimation of diastolic function may be challenging among patients with atrial fibrillation, data are presented for the entire cohort and patients in sinus rhythm separately.
Echocardiography
All echocardiograms were performed on a GE Vivid 5 or 7 (GE Medical System; Horten, Norway) ultrasound system. Echocardiograms were digitally stored on the same server and analyzed later by readers blinded to clinical data and functional status.
AVA was determined with quantitative Doppler using the continuity equation. The diameter of the LV outflow tract (LVOT) was measured 5 mm below the annulus from a zoomed image of the LVOT obtained in the parasternal long-axis view. Peak flow velocity across the valve was determined in the apical window or the echocardiographic window, where the highest peak velocity could be obtained by placing the continuous-wave Doppler cursor as parallel as possible with the flow across the valve. Peak transvalvular gradient was estimated using the modified Bernoulli equation. 6 Finally, the peak systolic flow velocity in the outflow tract was estimated with pulsed-wave Doppler. LVEF was estimated using the Simpson biplane method. 7 LV mass was estimated according to the joint recommendations of the American Society of Echocardiography (ASE) and the European Association of Echocardiography (EAE) using Devereux's formula. 8 LV wall thickness and dimensions were estimated from 2-dimensional (2D) images obtained in the parasternal long-axis view according to guidelines. LV mass index >116 g/m 2 in males and >100 g/m 2 in females was considered indicative of LV hypertrophy. Relative wall thickness (RWT) was calculated for assessment of LV geometry using the formula: 2×posterior wall thickness/LV diastolic diameter. 8 LA volume index (LAVi) was measured in LV end systole in the frame preceding mitral valve opening. The volume was measured using the biplane area length method and then corrected for body surface area.
Mitral inflow was assessed in the apical 4-chamber view using pulsed-wave Doppler with the sample volume placed at the tips of mitral leaflets during diastole. From the mitral inflow profile, the E-wave and A-wave peak velocities and deceleration time (DT) were measured. Doppler tissue imaging of the mitral annulus was obtained from the apical 4-chamber view using a sample volume placed in the lateral mitral valve annulus. Diastolic filling pattern was categorized according to the most recent EAE guidelines. 9 Stroke volume was estimated as product of the LVOT area and velocity time integral using the pulsed-wave Doppler. Cardiac index was calculated as the product of stroke volume and heart rate and indexed dividing by the body surface area.
Global strain was analyzed using EchoPAC PC 08 (GE Medical System; Horten, Norway) speckle tracking software 2D. Global strain was determined as the magnitude of strain at the aortic valve closure, and systolic strain rate was determined as the maximal negative strain rate value during the ejection phase. Both parameters were assessed in all 3 apical planes, and the mean values (mean global longitudinal strain [GLS] , mean systolic strain rate) were calculated. Frame rate was kept as high as possible with a minimum rate of 70/s.
Statistics
A P value <0.05 was considered significant. STATA/SE 12.0 (StataCorp LP; Texas) software was used for statistical analysis. Data are presented as mean±SD or number and percentages. Differences between groups were tested using Student t test, and categorical variables were tested by Fisher exact test.
Logistic regression analysis was performed, all variables with suspected clinical relevance were entered, variables were adjusted for age, history of hypertension, atrial fibrillation, or chronic obstructive pulmonary disease, and a multivariable model including all significant variables was created. Interaction terms were included in the multiple regression analysis to examine the potential modulating effect of clinically relevant covariates on symptomatic status. In addition to odds ratios, adjusted odds ratios for 1 SD were calculated, dividing the variable by the SD of the measure. Comparison of the predictive capability each method was performed by comparing the C-statistic derived from the area under the receiver operating characteristic curves using the generalized U-statistic as proposed by DeLong et al. 10 
Results
Of the 238 patients included in this study, 139 (58%) were judged to be asymptomatic. Table 1 provides baseline clinical data according to symptom status. Symptomatic patients were younger (72±10 versus 76±12 years of age; P=0.002) and presented less often with atrial fibrillation (13% versus 24%; P=0.05) and chronic obstructive pulmonary disease (2% versus 19%; P<0.001). However, patients considered asymptomatic had a considerable higher prevalence of hypertension and thus were more frequently treated with diuretics, calcium channel blockers, and β-blockers.
Despite similar AVAs between groups, patients with symptomatic AS had higher peak aortic valve flow velocities (3.9±0.8 versus 3.7±0.7 m/s; P=0.02) and lower velocities in the LVOT (0.95±0.22 versus 1.09±0.22 m/s; P<0.0001; Table 2 ). The presence of symptoms was associated with increased LVMi, interventricular septal thickness, LV posterior wall thickness, and increased RWT, reflecting LV concentric remodeling or concentric hypertrophy ( Table 2) .
Systolic function was similar between groups, with no significant differences in LVEF and GLS.
Symptomatic patients were more likely to have restrictive filling of the LV (19% versus 1%; P<0.001) and had shorter DT (199±58 versus 268±62 ms; P<0.0001), lower e′ sep velocities (6.5±1.7 versus 7.4±1.4 cm/s; P=0.04), and increased LAVi (49±18 versus 42±15 mL/m 2 ; P=0.02).
Factors Associated With Symptoms
Symptomatic status was associated with reduced LVOT velocity, increased aortic peak flow velocity, increased LVMi, increased RWT, increased LAVi, reduced DT, and reduced s'average ( Table 3 ). When adjusting for age, history of hypertension, history of atrial fibrillation, and chronic obstructive pulmonary disease in a multivariable logistic regression analysis, AV max , Doppler velocity at the LVOT (V LVOT ), LVMi, RWT, LAVi, e′, and DT were still associated with the presence of symptoms.
In multiple regression analysis using the aforementioned variables, DT emerged as an independent predictor of symptoms when adjusted for age, aortic valve velocity, LVMi, LAVi, RWT, and v LVOT (Table 3 ). Interaction terms were tested for interdependence between DT and age, LVMi, LAVi, RWT and V LVOT ,. All were found to be nonsignificant.
Receiver operating characteristic curves for DT, LVMi, LAVi, v LVOT , and LVEF are demonstrated in Figure 1 . C-statistics for DT were significantly higher than LVEF (P=0.0004), LAVi (P=0.008), and v LVOT (P=0.04), but despite higher area under the curve, demonstrated nonsuperiority to LVMi (0.82 versus 0.77; P=0.29).
The presence of diastolic dysfunction was strongly associated with symptom status because 94% of patients in grade 2 or 3 diastolic function were symptomatic as opposed to only 26% among patients with normal or grade 1 diastolic function ( Figure 2 ). In a model including the predefined variables, age, AV max , LVMi, LAVi, and DT provided incremental information on symptomatic status (Figure 3 ).
Discussion
The main finding in our study was that symptomatic status in severe AS was independently associated with the severity of LV remodeling, diastolic dysfunction, and LA volume increase. Particularly, for every 35 ms decrease in DT, there was a 2-fold increase of being symptomatic.
The hemodynamic consequence of aortic stenosis is LV pressure overload, causing morphological changes of the LV characterized by LV hypertrophy, concentric remodeling, and myocardial fibrosis. As a consequence of increased afterload 11 and LV remodeling, 4, 11, 12 AS will lead to LV diastolic dysfunction, increased filling pressures, and heart failure symptoms. The development of heart failure symptoms has previously been demonstrated to be associated with measures of AS severity and LV hypertrophy. 2, 13 Park et al 3 recently demonstrated that LV hypertrophy was more predominant in patients presenting with chest pain in AS irrespective of concomitant coronary artery disease. We similarly demonstrate an association between symptomatic status and AS severity and LVMi. We extend these findings as we demonstrate that concentric remodeling is associated with symptomatic status independent of LV hypertrophy and AS severity.
Recent studies have demonstrated that indices of LV systolic function assessed by speckle tracking are associated with the development of heart failure symptoms; 14, 15 we would thus a priori expect symptomatic patients to have a reduced LV function. Although we demonstrated lower s′ velocities in symptomatic patients, LVEF, stroke volume, and longitudinal GLS were similar, indicating that LV systolic function was equal between groups. Because s′ velocities are known to be load dependent, 16 it is likely that differences between groups reflect afterload differences rather than reduced LV function. In this context, it is thus interesting that we demonstrated significant differences in diastolic function because symptomatic patients more often presented with a pseudonormal or restrictive filling pattern.
Asymptomatic patients presenting with grade 2 or 3 diastolic function may constitute patients at especially high risk of developing symptoms, justifying closer surveillance and performance of exercise testing. Our findings are in accordance with the results published by Monrad et al, 13 which demonstrated in patients with AS that exercise-induced increase in filling pressures was most prominent among patients with reduced LV compliance. The same authors showed that even 10 years after AVR, as many as 30% would have increased filling pressures during exercise and that these patients were more likely to have a noncompliant LV cavity. It is thus possible that the presence of a restrictive filling pattern may identify patients who are less likely to benefit symptomatically from AVR.
In contrast, an abnormal relaxation pattern is both common in asymptomatic and symptomatic patients and provides no predictive information. This probably reflects that abnormal relaxation is common in the elderly population 17 and not always associated with elevated filling pressures, 9 but it may also reflect that the mitral flow pattern is load dependent and may change during exercise. 18 Symptomatic patients may thus have a grade 1 diastolic pattern during rest. The presence of increased filling pressures will, in time, cause dilatation of the LA. LA dilatation may thus identify patients with chronic or intermittent elevation of filling pressures presenting with abnormal relaxation or normal filling. Interestingly, only LAVi and not E/e′ was associated with symptom status, further suggesting that symptomatic patients with AS may have normal or mildly increased LV filling pressures at rest. 11, 13, 19 However, this finding also emphasizes the importance of ensuring that patients with severe AS and dilated LA are truly asymptomatic (for instance, by performing a treadmill test). Similarly, we demonstrated recently that LA volume dilatation is associated with a poor postoperative outcome 5 and might thus reflect that patients with severe LA dilatation have more advanced disease.
Interestingly, flow velocities in the LV outlet tract were reduced in symptomatic patients despite similar stroke volumes. This may be a consequence of impaired LV systolic function not detected by our measures, but more likely reflect a larger prevalence of patients with paradoxical low-flow AS as a consequence of more prominent concentric geometry and impaired diastolic function. The presence of reduced LVOT velocities and concentric remodeling should therefore raise the suspicion of symptomatic status. Despite similar AVAs, symptomatic patients presented with higher transvalvular gradients, and the ratio of LV outlet tract to transvalvular velocity was therefore reduced. Although this may suggest that symptomatic patients have more advanced disease, it may also demonstrate the limitation of AVA interpreting AS severity, even when LVEF is preserved. It is thus possible that differences in AS severity may explain to some extent the presence of symptoms in our population. Exercise tolerance may also have been associated with inability to increase cardiac output with exercise. This may also provide a link between diastolic dysfunction and AVAi indicates aortic valve area index; AV max , aortic peak flow velocity; D LVOT , diameter of the left ventricular outlet tract; GLS, global longitudinal strain; IVST, interventricular septum thickness; LAVi, left atrial volume index; LVEDD, LV end-diastolic diameter; LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; LVMi, LV mass index; LVPWT, LV posterior wall thickness; and V LVOT , Doppler velocity at the LV outflow tract. exercise intolerance, in which patients with diastolic dysfunction are characterized by an excessive increase in filling pressure to maintain cardiac output with exercise. Finally, we were not able to demonstrate significant differences in GLS between symptomatic and asymptomatic patients. This is surprising because recent data by Lancellotti et al 14 and Yingchoncharoen et al 15 on patients with moderatesevere AS demonstrated that GLS was associated with the combined end point of development of heart failure symptoms, a positive exercise test, cardiac death, or AVR. As GLS decreases with AS severity, 20 it is thus possible that GLS predicts the development of heart failure symptoms as a consequence of its correlation to AS severity. This view is supported by data from the same group who were not able to demonstrate that GLS was predictive in a multivariable model when corrected for well-established predictors including AS severity. 21 However, it could also be speculated that reduced GLS instead of reflecting symptom status may identify patients with excessive cardiac remodeling 22, 23 who are more likely to develop heart failure symptoms and have a poor outcome. 23 In line with this, we recently demonstrated that GLS is associated with postoperative outcome after AVR in symptomatic patients. 22 
Study Limitations
Assessment of symptoms is challenging. Because symptoms develop gradually, and some patients may adapt to symptoms by avoiding activities that may cause dyspnea, this may especially be the case in an elderly population. This likely explains the apparent paradox that symptomatic patients were younger than asymptomatic patients. Although asymptomatic patients were evaluated by senior consultants with extensive experience in evaluating patients with heart valve diseases, symptomatic patients were evaluated according to New York Heart Association class and Canadian Cardiovascular Society class; the optimal approach would have been to perform a prospective study with meticulous assessment of exercise capacity and symptomatic status. Given this limitation, the present study should be interpreted as primarily hypothesis generating. Thus, we cannot exclude the possibility that symptomatic patients were present in our asymptomatic population; however, this potential bias would reduce the observed differences. Although symptoms in our patients were attributed to their AS, it is possible that symptoms were instead attributable to coexistent coronary arterial disease or pre-existing diastolic dysfunction. No echocardiographic studies prior to diagnosis of AS were available in patients with a restrictive physiology. Although none of the patients were diagnosed with amyloid of other restrictive cardiomyopathies, we cannot exclude the possibility that these patients had a primary diastolic dysfunction rendering the patient especially sensitive to the pressure overload caused by AS. In our population, >70% of the asymptomatic patients had hypertension. Because hypertension is known to reduce transvalvular gradients in AS 24 and gradients are associated with LAVi, 25 differences in prevalence of hypertension between groups may potentially have introduced a bias, reducing the importance of LAVi in differentiating symptomatic status. The use of valvuloarterial impedance could possibly have addressed this limitation. We have no data on mitral annular calcification, a factor known to affect the assessment of diastolic function, and thus, data have to be interpreted cautiously.
In light of study design, the present study should be considered hypothesis generating, and future studies with a systematic symptom assessment using an exercise test should be performed prospectively to confirm our finding.
LV structure was assessed by echocardiography, and no histological examinations were performed; thus, we can only speculate on the degree of myocardial fibrosis. No direct hemodynamic measurements of LV end-diastolic or LA pressure were performed. However, E/e′ is accepted as a wellvalidated surrogate in a wide range of patients with cardiac disease, including AS. 19 
Conclusion
The present study demonstrates that symptomatic status in severe AS is associated with impaired diastolic function, LV hypertrophy, concentric remodeling, and LA dilatation when corrected for indices of aortic valve severity.
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